SUBSCRIBE
SUBSCRIBE
News   Policy

Amylin Pharmaceuticals, Inc. Says Key Diabetes Drug to Launch this Year

January 28, 2010 | 
1 min read
Bookmark and Share

Reuters -- Amylin Pharmaceuticals Inc said on Wednesday it expects to begin selling the long acting version of its Byetta diabetes drug this year and sees "a clear path to sustained profitability."
Regulatory
MORE ON THIS TOPIC
Podcast
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
July 16, 2025
 · 
1 min read
 · 
Heather McKenzie
Entrance to the U.S. Department of Health and Human Services in Washington, DC
Layoffs
HHS Begins Formally Laying Off Employees
July 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Policy
FDA Commissioner Marty Makary Proposes Lowering Industry User Fees
July 15, 2025
 · 
2 min read
 · 
Tristan Manalac
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
 · 
6 min read
 · 
Lori Ellis